After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
A late-stage trial for Amgen’s (AMGN) drug ABP 980 shows its ‘non-inferiority’ to Roche’s (RHHBY) biosimilar branded product.
TheStreet highlights 3 stocks pushing the health services industry lower today.
A look at who will be up and who will down this earnings season.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.